Skip to main content

AstraZeneca allows Teva to market generic Entocort EC

Alaric DeArment
5/18/2010

JERUSALEM Teva Pharmaceutical Industries and AstraZeneca have reached a settlement that will allow Teva to market its generic version of a drug for treating Crohn’s disease, the Israeli generic drug maker said Tuesday.

Teva will begin marketing budesonide capsules in February 2012, a generic version of AstraZeneca’s Entocort EC.

Entocort EC capsules have annual sales of around $265 million, according to IMS Health. The drug will lose patent protection as a treatment for adults with Crohn’s disease in July 2014 and lose protection as a treatment for children in January 2015, according to Food and Drug Administration records.

Related Topics

Popular Articles

Walgreens buyout reportedly could result in three divisions

Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields Health Solutions—could become three independent divisions, per a report.
walgreens

Ulta Beauty sets date for experiential beauty event

Ulta Beauty World will take place on April 26 in San Antonio, Texas.
ulta beauty

CVS Health to open smaller format stores

Each location will average less than 5,000 square feet and will feature a full-service pharmacy with limited over-the-counter products available for purchase.
cvs smaller format

Walgreens reportedly close to roughly $10B deal to go private

The deal could be finalized by Thursday, per a WSJ report.
walgreens boots alliance

Costco to raise hourly pay, reaches tentative agreement with union

Costco also is adding vacation time for new employees during their first year and giving workers with 30 years of employment an additional week of time off, per a CNN report.
costco teaser
X
This ad will auto-close in 10 seconds